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We investigated the association of survivin expression with prognosis and other apoptosis-related biological factors in 110 primary
ovarian cancer patients admitted to the Division of Gynecologic Oncology, Catholic University of Rome. Immunohistochemistry was
performed on formalin-fixed, paraffin-embedded sections by using polyclonal antibody ab469 for survivin, and mouse monoclonal
antibodies (clone 124 and DO-7), for bcl-2 and p53, respectively. Cytoplasmic survivin immunoreaction was observed in 84.5% cases,
while nuclear survivin immunostaining was observed in 29.1% cases. We failed to find any relationship between cytoplasmic survivin
positivity rate and any of the parameters examined. Serous tumours showed a lower percentage of nuclear survivin positivity with
respect to other histotypes (20.5 vs 48.6%, respectively; P-value¼0.004). The percentage of nuclear survivin positivity was higher in
cases subjected to primary tumour cytoreduction (43.5%), with respect to patients subjected to exploratory laparotomy (20%)
(P¼0.024). Bcl-2 and p53 were, respectively, expressed in 27.3 and 60.0% of the cases and their expression was not correlated with
survivin status. During the follow-up period, progression and death of disease were observed in 68 (61.8%) and 53 (48.2%) cases,
respectively. There was no difference in time to progression and overall survival according to survivin status in ovarian cancer patients.
In conclusion, in our experience, the immunohistochemical assessment of survivin status does not seem to be helpful in the
prognostic characterisation of ovarian cancer. A more in depth investigation of the complex physiology of divergent survivin variants is
needed in order to clarify the biological and the clinical role of differentially located survivin isoforms.
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Although several clinicopathological parameters have been re-
ported to be of prognostic significance in ovarian cancer, including
F.I.G.O. stage, volume of residual disease, presence of cytologically
malignant ascites and grade of tumour differentiation (Hoskins
et al, 2000), it is conceivable that the assessment of biochemical
factors more strictly related to tumour cell biology and intrinsic
aggressiveness could help identifying high-risk patients and
facilitating management of this disease.
Apoptosis (programmed cell death) has been proposed to play a
role not only in cancer onset and progression but also in
sustaining decreased tumour cell sensitivity to chemotherapy
(Hickman, 1992; Thompson, 1995), which still represents one of
the main prognostic indicators in this neoplasia (Hoskins et al,
2000). In this context, the analysis of the molecules possibly
involved in the modulation of apoptosis seems to be particularly
attractive.
Survivin is a member of the inhibitors of apoptosis protein
(IAP) family, which participates in the complex network regulating
programmed cell death and also cell division (Ambrosini et al,
1997; Altieri and Marchisio, 1999; Salvesen and Duckett, 2002).
Survivin protein is commonly detected in fetal tissues but not in
normal adult tissues, while being overexpressed in human cancer,
thus suggesting the contribution of survivin gene reactivation in
carcinogenesis (Ambrosini et al, 1997). The crucial role of survivin
in protection from apoptosis is supported by the observations that
forced expression of survivin counteracts cell death induced by
several apoptotic stimuli (Li et al, 1998), while survivin inhibition
by antisenses causes spontaneous apoptosis (Olie et al, 2000).
Survivin activity seems to be mediated by the inhibition of caspase
pathways and also interaction with the microtubules of the mitotic
spindle during the G2/M phase of cell cycle (Deveraux and Reed,
1999; Li, 2003), which suggest that survivin could promote tumour
growth by dual functions, that is, inhibition of apoptosis and
induction of mitogenesis. Overexpression of survivin has been
associated with parameters of aggressiveness and poor prognosis
in several solid tumours, although conflicting data have also been
reported (Li, 2003). As far as ovarian lesions are concerned, a
higher percentage of survivin overexpression was found in
borderline and malignant tumours with respect to benign lesions
(Sui et al, 2002).
Several studies have attempted to delineate the clinical role of
survivin expression in epithelial ovarian carcinomas but no
definitive conclusions could be drawn probably because of the
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ssize and/or heterogeneity of the population series, incompleteness
of clinical informations as well as the use of different antibodies
and methods of score of survivin expression (Yoshida et al, 2001;
Sui et al, 2002; Takai et al, 2002; Zaffaroni et al, 2002; Cohen et al,
2003).
The aim of this study was to investigate the association of
survivin expression with surgical data, response to chemotherapy
and prognosis in a series of primary ovarian cancer patients
undergoing surgery, chemotherapy treatment, and follow-up
performed by the same gynaecological oncology team. Moreover,
considering the biological relevance of the apoptosis regulatory
proteins such as p53 and bcl-2 in the complex regulation of
apoptosis (Miyashita and Reed, 1993; Miyashita et al, 1994), the
association of survivin with these biological parameters has been
also investigated.
MATERIALS AND METHODS
Patients
The study included 110 primary ovarian cancer patients admitted
to the Division of Gynecologic Oncology, Catholic University of
Rome between May 1986 and September 2002. The median age was
58.5 years (range 25–84). A total of 91 (82.7%) patients were stage
III–IV. The other clinicopathological characteristics are listed in
Table 1. According to the standard guidelines for ovarian cancer
primary treatment, maximal surgical effort has been attempted in
all patients resulting in successful debulking in 65 (59.1%) cases,
which were subjected to surgical removal of tumour masses, along
with total abdominal hysterectomy, adnexectomy, radical omen-
tectomy, appendectomy and multiple biopsies, and additional
surgery (intestinal resection, diaphragm stripping) when required.
Radical pelvic and para-aortic lymphadenectomy was performed
in all patients undergoing primary cytoreduction who had absent
or microscopic residual disease or residual tumour less than 2cm.
In total, 45 (40.9%) cases were judged to be unresectable at first
surgery because of extensive peritoneal bulky carcinomatosis,
agglutinated bowel/mesentery and infiltration of the upper
gastrointestinal tract and/or the major vessels (Fanfani et al,
2003), and were submitted only to multiple biopsies.
Patients cytoreduced at first surgery received 4–6 cycles of
chemotherapy 2–3 weeks after primary surgery, unless they
showed clinical progression during treatment. As far as patients
undergoing explorative laparotomy are concerned, they received
three or four cycles of neoadjuvant chemotherapy before attempt-
ing a second cytoreductive surgery, unless they showed clinical
progression during treatment. All patients underwent platinum-
based chemotherapy (cisplatin: 75–100mgm
 2 for each cycle or
carboplatin 5 AUC, q21), including also paclitaxel in 61 (58.6%)
cases.
Response to chemotherapy was assessed by gynaecological
exam, ultrasound examination, analysis of CA125 levels and CT
scan, if necessary, and was recorded according to World Health
Organization criteria (1979). In the subgroup of patients who were
not susceptible to be cytoreduced at first surgery, a direct
assessment of response to chemotherapy was carried out in case
of clinical response, at the time of second laparotomy.
Immunohistochemistry
Tumour tissues’ biopsies from primary tumours were obtained at
first surgery in all cases. Tissue specimens were fixed in formalin
and paraffin-embedded according to standard procedures. In all,
3mm of representative blocks from each case were deparaffinised
in xylene, rehydrated, treated with 3% H2O2 in TBS for 5min to
block endogenous peroxidase activity, and subjected to heat-
induced epitope retrieval in microwave oven using 10mM citric
acid at pH 6.0. Sections were incubated with normal goat serum
20% for 30min, then with polyclonal antibody ab496 (ABCAM
Limited, Cambridge, UK) diluted according to the manufacturer’s
instructions, overnight. Bcl-2 and p53 were analysed using mouse
monoclonal antibodies (clone 124 and DO-7, respectively, DAKO,
Carpintera, CA, USA), according to the methods previously
described (Ferrandina et al, 1999; Ferlini et al, 2003).
Slides from all cases studied were then simultaneously processed
for immunohistochemistry using En Vision-rabbitþSystem-HRP
DAKO (Carpintera, CA, USA). Diaminobenzidine was used as a
chromogen (DAB substrate System, DAKO). Negative controls
were performed using nonimmunised rabbit serum or by omitting
the primary antiserum.
The analysis of all tissue sections was carried out without any
prior knowledge of the clinical parameters by three authors (MG,
LL, FL) by means of light microscopy. Proportion of immunos-
tained cells was scored at low magnification ( 5 objective lens) by
evaluating the entire tumour area. The intensity of staining (scale
0–4) and the percentage of stained cells were evaluated. The
following cutoff were ‘a priori’ chosen for scoring: cases with more
than 20% of cells showing intensity of cytoplasmic staining 41
were considered positive for cytoplasmic survivin expression,
while cases with nuclear staining X1 in more than 5% of cells were
considered as nuclear survivin positive. In case of disagreement
(n¼13, 11.8%), sections were submitted to a rejoint evaluation.
Statistical analysis
Fisher’s exact test or w
2 test were used to analyse the distribution of
surviving-positive cases according to clinicopathological, surgical,
and biological features.
Overall survival (OS) and time to progression (TTP) were
calculated from the date of diagnosis to the date of death/
progression or date last seen. Medians and life tables were
computed using the product-limit estimate by the Kaplan and
Meier method (1958), and the log-rank test was employed to assess
Table 1 Patient characteristics
Characteristics No. of patients (%)
All cases 110
Age (years)
o60 56 (50.9)
X 60 54 (49.1)
Ascites
No 47 (42.7)
Yes 63 (57.3)
Histotype
Serous 73 (66.4)
Mucinous 4 (3.6)
Endometrioid 21 (19.1)
Undifferentiated 7 (6.4)
Clear cell 3 (2.7)
n.a. 2 (1.8)
Grade
G1–2 26 (23.4)
G3 74 (67.3)
n.a. 10 ( 9.3)
FIGO stage
I–II 19 (17.3)
III–IV 91 (82.7)
Response to chemotherapy
a
Complete/partial 68 (74.7)
No change/progression 23 (25.3)
aOnly FIGO stage III–IV.
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sthe statistical significance (Mantel, 1966). Statistical analysis was
carried out using SOLO (BMDP Statistical Software, Los Angeles,
CA, USA).
RESULTS
Survivin immunostaining
As shown in Figure 1, specific survivin immunostaining was
observed both in the cytoplasm and nuclear compartment (A) of
tumour cells, or only in the cytoplasm (B) or nucleus (C).
Cytoplasmic survivin immunoreaction was observed in 93
(84.5%) cases, while nuclear survivin immunostaining was
observed in only 32 (29.1%) cases: 29 (26.4%) cases showed
survivin staining both in nuclear and cytoplasmic compartment.
There seems to be no association between cytoplasmic and
nuclear survivin staining; however, nine out of 13 (69.2%) cases
with very strong cytoplasmatic intensity (score¼4) showed also
nuclear staining in contrast with only 19 out of 80 (23.7%) cases
with lighter (score¼2,3) cytoplasmic staining (P¼0.002).
Correlation with clinical, surgical and pathological
parameters
Table 2 shows the distribution of cytoplasmic and nuclear survivin
positivity according to clinicopathological characteristics. As far as
cytoplasmic survivin reaction is concerned, we failed to find any
relationship between positivity rate and any of the clinicopatho-
logical parameters examined. As far as nuclear survivin expression
is concerned, serous tumours showed a lower percentage of
nuclear survivin positive immunoreaction with respect to other
histotypes (20.5 vs 48.6%, respectively; P-value¼0.004). On the
other hand, nuclear survivin staining was not differently
distributed according to other clinical–pathological parameters.
No association between survivin status and response to chemo-
therapy was found. Moreover, neither nuclear nor cytoplasmic
survivin staining were found to be associated with response to
treatment in subgroups of patients receiving platinum-based vs
paclitaxel-containing chemotherapy (data not shown).
Table 3 shows the distribution of cytoplasmic and nuclear
survivin expression according to surgical features in stage III–IV
ovarian cancer patients.
Cytoplasmic survivin immunostaining was not differently
distributed according to any of the parameters analysed.
On the other hand, the percentage of nuclear survivin positivity
was higher in cases in which tumour cytoreduction was achieved at
primary surgery (20 out of 46, 43.5%) with respect to patients
subjected to exploratory laparotomy (nine out of 45, 20%)
(P¼0.024). Nuclear survivin staining was found not to be different
according to the extent of debulking since nuclear survivin
positivity was found in seven out of 16 (43.7%) cases achieving
optimal cytoreduction (residual tumour o0.5cm) vs 13 out of 30
(43.3%) patients achieving suboptimal (residual tumour X0.5cm)
debulking (P-value¼n.s.).
We found a higher percentage of nuclear survivin positivity in
patients with no apparent mesenteric infiltration (24 out of 60,
40.0%) with respect to patients with tumour mesenteric involve-
ment (5 out of 31, 16.1%, P-value¼0.017). In addition, the
percentage of nuclear survivin positivity was also higher in cases
without spread of disease in the upper region of the abdo-
men (52.2%) with respect to patients with this feature (24.3%,
P-value¼0.014).
Correlation with apoptosis-related parameters
Bcl–2 and p53 expression was evaluated in 80 cases. Bcl-2 and p53
were expressed in 27.3 and 60.0%, respectively, of the cases
examined. As shown in Table 4, neither cytoplasmic or nuclear
survivin immunostaining were differently distributed according to
any of the apoptosis-related parameters analysed.
Survival analysis
Follow-up data were available for 110 patients. As of May 2004, the
median follow up was 32 months (range 1–221). During the
Figure 1 Survivin immunostaining in primary ovarian cancer. Specific survivin immunostaining was observed in both the cytoplasm and the nuclear
compartment (A), either in the cytoplasm only (B), or in nuclear compartment only (C). An example of surviving-negative ovarian tumour (D).
Bar¼35mm.
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sfollow-up period, progression and death of disease were observed
in 68 (61.8%) and 53 (48.2%) cases, respectively.
As shown in Figure 2, there was no difference in TTP according
to cytoplasmic and nuclear survivin status in ovarian cancer
patients. Similar results were observed when considering the OS
curves (data not shown).
DISCUSSION
Despite the availability of several studies exploring the expression
of survivin protein in primary ovarian cancer, no definitive
conclusions have been provided about its possible clinical role in
this neoplasia (Yoshida et al, 2001; Sui et al, 2002; Takai et al, 2002;
Table 2 Nuclear and cytoplasmic survivin expression according to clinical and pathological characteristics in ovarian cancer
Characteristics No. of patients
Cytoplasmic survivin positive
No. (%) P-value
a
Nuclear survivin positive
No. (%) P-value
a
All cases 110 93 (84.5) 32 (29.1) —
Age (years)
o60 56 47 (83.9) 18 (32.1)
X60 54 46 (85.2) 0.9 14 (25.9) NS
Ascites
No 47 39 (82.9) 14 (30.4)
Yes 63 54 (85.7) 0.4 18 (30.0) 0.3
—
Histotype
Serous 73 62 (84.9) 15 (20.5)
Mucinous 4 3 (75.0) 2 (50.0)
Endometrioid 21 19 (90.5) 8 (38.1)
Undifferentiated 7 6 (85.7) 5 (71.4)
Clear cell 3 1 (33.3) 0.9
b 2 (66.7) 0.004
b
n.a. 2 —
Grade
G1–2 26 19 (73.0) 7 (26.9)
G3 74 65 (87.8) 25 (33.8)
n.a. 10 — 0.3 — 0.3
FIGO stage
I–II 19 15 (78.9) 3 (15.8)
III–IV 91 78 (85.7) 0.5 29 (31.9) 0.2
Response to chemotherapy
c
Complete/partial 68 59 (86.8) 20 (29.4)
No change/progression 23 19 (82.6) 0.4 8 (34.8) 0.4
aCalculated by Fisher’s exact test for proportion.
bSerous vs other histotypes.
cOnly FIGO stage III–IV. NS¼not significant. Bold indicates significant P-values.
Table 3 Nuclear and cytoplasmic survivin expression according to surgical parameters in stage III–IV ovarian cancer
Characteristics No. of patients
Cytoplasmic survivin positive
No. (%) P-value
a
Nuclear survivin positive
No. (%) P-value
a
All cases 91 78 (85.7) 29 (31.9) —
Surgery
Cytoreduction 46 39 (84.8) 20 (43.5)
Explorative laparotomy 45 39 (86.7) 0.9 9 (20.0) 0.024
Carcinomatosis
No 25 19 (76.0) 10 (40.0)
Yes 66 59 (89.4) 0.1 19 (28.8) 0.20
Mesenteric infiltration
No 60 52 (86.7) 24 (40.0)
Yes 31 26 (83.9) 0.5 5 (16.1) 0.017
Frozen pelvis
No 61 52 (85.2) 18 (29.5)
Yes 30 26 (86.7) 0.6 11 (36.7) 0.3
High diaphragmatic spread
No
Yes 23 19 (82.6) 12 (52.2)
70 59 (84.3) 0.5 17 (24.3) 0.014
aCalculated by Fisher’s exact test for proportion. Bold indicates significant P-values.
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sZaffaroni et al, 2002; Cohen et al, 2003). As emphasised in Table 5,
discrepancies among studies can be explained by size and clinical
characteristics of the series examined (Yoshida et al, 2001; Sui et al,
2002; Takai et al, 2002; Cohen et al, 2003), as well as
methodological differences: indeed, different antibodies as well
as scoring systems for evaluation of survivin immunoreaction have
been utilised. Moreover, survivin staining has been described as
prevalent either in the cytoplasm (Yoshida et al, 2001; Takai et al,
2002; Zaffaroni et al, 2002) or in the nucleus (Sui et al, 2002; Takai
et al, 2002; Cohen et al, 2003), and it has been not always clearly
stated whether the overall rate of positivity was derived from a
single subcellular compartment or both.
We first separately describe the expression of survivin protein in
cytoplasmic and nuclear compartments of ovarian tumour cells.
With the use of ab496 antibody, survivin was shown to be
predominantly detected in the cytoplasmic compartment of
ovarian cancer cells, confirming previous observations obtained
with the same antibody after subcellular fractionation of HeLa cells
(Fortugno et al, 2002). In particular, Fortugno et al (2002) showed
that cytoplasmic and nuclear survivin pools are immunochemi-
cally different and this might partly explain the conflicting data on
survivin localisation in solid tumours (Li, 2003). Besides,
cytoplasmic and nuclear survivin are independently modulated
during cell cycle progression and only cytoplasmic survivin
associates with p34
cdc2 and is phosphorylated on Thr34, event
which seems to mediate the antiapoptotic function of the protein
(O’Connor et al, 2000), thus suggesting that the two pools exert
different biological functions. Moreover, data have been provided
about the existence of functionally divergent survivin splice
variants, which exhibit different subcellular localisations (Mahotka
et al, 2002).
The relationship between immunohistochemically detected
cytoplasmic and nuclear localisation of survivin has been not
investigated: although we failed to find any relationship between
cytoplasmic and nuclear staining, a higher percentage of cases with
very strong cytoplasmic intensity showed also nuclear survivin
immunoreaction. Further studies aimed at clarifying the functional
relationship between cytoplasmic and nuclear survivin are needed
in order to properly assess the role of immunohistochemically
detected survivin pools in human cancer.
As far as the association between survivin and clinicopatholo-
gical and surgical parameters is concerned, we showed that serous
ovarian tumours expressed a significantly lower nuclear survivin
content with respect to other histotypes, as also reported by
Yoshida et al (2001). Moreover, an intriguing association between
high expression of nuclear survivin and better chance of
performing tumour cytoreduction at first surgery was shown,
which is likely to be supported by the association of higher nuclear
survivin content with the absence of distinctive patterns that
usually preclude the feasibility of cytoreduction, such as tumour
involvement of upper abdominal organs and mesentery (Fanfani
et al, 2003). Our data are unlikely to be influenced by the initial
tumour extension, since no correlation between survivin expres-
sion and stage of disease was found, as previously reported (Sui
et al, 2002; Zaffaroni et al, 2002). However, the association between
high nuclear survivin expression and better chance of cytoreduc-
tion, which represents one of the major determinants of response
to chemotherapy and favourable prognosis (Hoskins et al, 2000),
does not seem to translate into major differences in clinical
outcome, perhaps because of the interference of other factors such
as chemotherapy responsiveness or other yet unknown biological
characteristics.
Our data seem to go against the original hypothesis that survivin
might predict a more aggressive clinical outcome, although some
evidences have been reported documenting the absence of any
association between survivin expression and prognosis in some
solid tumours (Grabowski et al, 2003; Li, 2003), and even a
favourable prognostic role of high nuclear survivin content in
gastric and bladder tumours (Okada et al, 2001; Lehner et al,
2002). The possibility that the biological and clinical role of
survivin expression might also be influenced by tissue specificity
cannot be ruled out and deserves further attention.
In vitro evidences showed that survivin might counteract
chemotherapy-induced apoptosis (Zaffaroni et al, 2002), although
univocal data have not been reported (Grossman et al, 2001;
Pennati et al, 2002), possibly because of the use of different cell
systems or the occurrence of peculiar surviving–cytotoxic drug
Table 4 Cytoplasmic and nuclear survivin expression according to apoptosis-related parameters in ovarian cancer
Characteristics No. of patients
Cytoplasmic survivin positive
No. (%) P-value
a
Nuclear survivin positive
No. (%) P-value
a
Bcl-2 status
Negative 58 48 (82.7) 23 (9.6)
Positive 22 17 (77.3) NS 7 (31.8) NS
P53 status
Negative 32 28 (87.5) 9 (28.1)
Positive 48 41 (85.4) NS 14 (29.2) NS
aCalculated by Fisher’s exact test for proportion. NS¼not significant.
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Figure 2 Time to progression (TTP) curves according to cytoplasmic
(A) and nuclear (B) survivin status in ovarian cancer.
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sinteractions: for instance, survivin is able to bind polymerised
microtubules through a putative tubulin-binding domain in the
extended survivin C-terminal a-helix (Verdecia et al, 2000), and
counteract paclitaxel-induced apoptosis in NIH3T3 fibroblasts (Li
et al, 1998). In clinical studies, Zaffaroni et al (2002) showed that
high levels of survivin protein are associated with resistance to
regimens containing the microtubule-targeting agent paclitaxel,
but are unrelated to cisplatin responsiveness in advanced ovarian
cancer. However, no data on the clinical relevance of this finding in
terms of patient clinical outcome have been provided (Zaffaroni
et al, 2002).
In the current series, which included patients with measurable
disease at first surgery in order to give a better evaluation of
chemotherapy response, we failed to find any association between
cytoplasmic or nuclear survivin expression and response to
chemotherapy, even after subgrouping patients administered
platinum-based vs paclitaxel-containing regimens. In addition,
we could not find any difference in terms of TTP and OS according
to either cytoplasmic or nuclear survivin status, in contrast with
earlier studies which reported a negative prognostic role of
survivin overexpression (Yoshida et al, 2001; Sui et al, 2002; Takai
et al, 2002). However, it has to be taken into account that this is the
first study examining the clinical relevance of survivin status in
terms of clinical outcome in a single-institution large series of
ovarian carcinomas, compared to previous reports which referred
to very small sample series (Yoshida et al, 2001; Sui et al, 2002;
Takai et al, 2002), sometimes biased by the inclusion of selected
groups of patients (Yoshida et al, 2001).
Finally, the association between survivin, p53 and bcl-2 protein
has been investigated based on the following background: (i) in the
complex regulation of apoptosis and cell cycle progression, p53
and bcl-2 play a crucial role (Miyashita and Reed, 1993; Miyashita
et al, 1994); (ii) wild-type p53 has been shown to negatively
regulate human survivin at both mRNA and protein levels in 2774
ovarian carcinoma cells (Mirza et al, 2002), and to suppress
survivin expression in lung adenocarcinoma cells (Hoffman et al,
2002); (iii) survivin expression has been associated with mutant
p53 accumulation in ovarian and gastric cancer (Lu et al, 1998;
Cohen et al, 2003), and during colorectal carcinogenesis (Kawasaki
et al, 2001); moreover, a coassociation of survivin and bcl-2 has
been found in breast and gastric cancer (Tanaka et al, 2000;
Kawasaki et al, 2001). Our study, as well as other reports (Zaffaroni
et al, 2002; Cohen et al, 2003), failed to show any relationship
between p53 or bcl-2 and survivin expression, suggesting that
these proteins could exert their functions through different
mechanisms.
In conclusion, in our experience on a large series of patients, the
immunohistochemical assessment of cytoplasmic and nuclear
survivin status does not seem to be helpful in the prognostic
characterisation of ovarian cancer. However, a more in depth
investigation of the complex physiology of divergent survivin
variants is needed in order to clarify the biological and possibly the
clinical role of differentially located survivin isoforms.
Moreover, it is conceivable that, even though survivin has no
prognostic role in ovarian cancer, it might be a potential target for
apoptosis-based therapy, as testified by the increasing number of
approaches aimed at (i) blocking survivin in cancer cells by small
molecule antagonists, antisense oligonucleotides, ribozymes,
dominant negative mutants (Reed and Wilson, 2003) or (ii)
utilising survivin to create a tumour vaccine with dendritic cells
(Pisarev et al, 2003; Reed and Wilson, 2003).
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